Analysis Clinical trials

Clearmind's Hong Kong PTSD patent application is published, not granted

A published application for psychedelic-derived PTSD compounds signals IP positioning, not clinical or regulatory progress. Trial teams should read it that way.

VigiEye editorial · Fri 20 Nov 2026

What happened

On 19 November 2026, Clearmind Medicine Inc. said a Hong Kong patent application covering psychedelic-derived compounds for PTSD and other mental health disorders has been published. The company's statement, filed as an exhibit with the US Securities and Exchange Commission, is explicit on one point: no patent has yet been granted.

That qualifier shapes everything else. The records give no details on the compounds, the claims, the filing date or any clinical programme behind the application. They also do not say whether the compound has been tested in people. Those points are not yet known from the material available, and this article does not fill them in.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on VigiEye and CompePharma
  • One subscription for both sites, cancel any time
Continue with Google
or
You'll be signed in straight away; we also email you a link to confirm your address. Reading every article takes a $4.99/month subscription (secure checkout by Stripe), billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. See our terms and privacy policy.

Sources this analysis is based on

Written by VigiEye's editorial system with AI assistance (model claude-sonnet-5-5) strictly from the official records listed above. It can contain errors: check the sources before acting. Not legal, medical or investment advice.

More analysis & opinionAll →